Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT05203965
EARLY_PHASE1

Functional Neuroimaging of Alcoholism Vulnerability: Probing Glutamate and Reward, Using the mGluR5 Inhibitor Mavoglurant

Sponsor: Yale University

View on ClinicalTrials.gov

Summary

The purpose of this study is to evaluate the role of Mavoglurant in clarifying the neurobiology of alcoholism risk. This is a one-site, randomized, within subjects, counterbalanced double-blind study of a single dose (200mg) of Mavoglurant and placebo.

Key Details

Gender

All

Age Range

18 Years - 45 Years

Study Type

INTERVENTIONAL

Enrollment

80

Start Date

2022-05-17

Completion Date

2026-07-31

Last Updated

2025-10-09

Healthy Volunteers

Yes

Interventions

DRUG

Mavoglurant (AFQ056)

Two 100mg tablets of Mavoglurant will be administered on the morning of one of the two experimental days by a RN or the physician investigator.

DRUG

Placebo

Two matching tablets of placebo will be administered on the morning of one of the two experimental days by an RN or the physician investigator.

Locations (1)

Hartford Hospital

Hartford, Connecticut, United States